Health
Study finds some antibody therapies cannot combat new COVID variants – European Pharmaceutical Review
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against new SARS-CoV-2 variants, while other antibodies were not.
Posted: 28 January 2021 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against the new SARS-CoV-2 variants, while other antibody therapies, including Eli Lillys bamlanivimab, were not.
New research suggests that new variants of the SARS-CoV-2 virus are more resistant to neutralisation with antibody therapies, including convalescent plasma and vaccinee sera. According to the authors of the paper, currently…
-
Noosa News24 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
General22 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News19 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
Noosa News22 hours agoMan dies in Gold Coast after rolling trailer pins him to lamp-post